Skip to main content
. Author manuscript; available in PMC: 2009 Dec 1.
Published in final edited form as: Toxicol Appl Pharmacol. 2008 Aug 26;233(2):193–202. doi: 10.1016/j.taap.2008.08.011

Fig. 3.

Fig. 3

Chlordecone inhibits LXRs and activates FXR. (A) Structure of chlordecone (CD). (B) HEK 293 cells were cotransfected with a luciferase reporter plasmid [(LXRE)3 Tklc] containing three copies of the LXR response element upstream of the thymidine kinase (TK) promoter and expression vector for murine LXRα and RXR along with the CMX-β-gal internal control. (C) HEK 293 cells were cotransfected as in B for LXRβ and RXR. Cells were treated with vehicle (ethanol) alone or 0.1 to 50 μM CD and/or 1 μM T0901317 (LXR agonist) or 100 nM LG268 (RXR agonist) as indicated. (D) HEK 293 cells were cotransfected with a luciferase reporter plasmid [(FXRE) Tklc] construct containing an FXR response element upstream of the TK promoter and expression vector for FXR and RXR. Cells were treated with vehicle (ethanol) alone or 50 μM CD and/or 100 nM LG268 (RXR agonist) as indicated. Values were presented as the mean relative luciferase units (RLU) from triplicate assays±SE. Significant differences from appropriate controls detected as described in Materials and methods were indicated by an asterisk.